U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07054879) titled 'CtDNA-guided Maintenance Therapy in Pancreatic Cancer' on June 27.
Brief Summary: This study aims to conduct a large-scale prospective clinical trial to evaluate the efficacy and safety of capecitabine monotherapy as maintenance treatment following standard adjuvant chemotherapy (gemcitabine plus capecitabine) in patients with resectable pancreatic cancer, and to analyze whether ctDNA-MRD testing can guide the selection of postoperative maintenance therapy.
Study Start Date: Nov. 01, 2024
Study Type: OBSERVATIONAL
Condition:
Pancreatic Cancer
Recruitment Status: RECRUITING
Sponsor: The Affiliated Nanjing Drum Tower Hospital of ...